Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk reports positive data from semaglutide diabetes trial

Novo Nordisk reports positive data from semaglutide diabetes trial

13th July 2015

Novo Nordisk has announced positive findings from SUSTAIN1, the first phase IIIa trial assessing semaglutide, a new weekly GLP-1 analogue therapy for type 2 diabetes.

The trial investigated the efficacy and safety of semaglutide as a monotherapy during 30 weeks of treatment in 388 people with type 2 diabetes previously on diet and exercise, with performance compared to placebo.

Its primary objective was achieved after it was revealed that the new drug offered better control of blood sugar levels than placebo, while use of the therapy was also associated with improved rates of weight loss.

Novo Nordisk expects to announce headline results of the five remaining SUSTAIN trials within the next nine months.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "We are excited about these results, which confirm that semaglutide has the potential to help people with type 2 diabetes achieve both good glycaemic control and a significant weight loss with one weekly injection."

Last month, the company's insulin detemir therapy Levemir was recommended for EU approval in children with diabetes as young as one year old.ADNFCR-8000103-ID-801794065-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.